"On December 1, people throughout the world observe World AIDS Day, an opportunity for the global community to honor those living with HIV; the families, friends, caregivers, and communities who support them; and those who have lost their lives to"...
CRIXIVAN in combination with antiretroviral agents is indicated for the treatment of HIV infection. This indication is based on two clinical trials of approximately 1 year duration that demonstrated: 1) a reduction in the risk of AIDS-defining illnesses or death; 2) a prolonged suppression of HIV RNA.
DOSAGE AND ADMINISTRATION
The recommended dosage of CRIXIVAN is 800 mg (usually two 400-mg capsules) orally every 8 hours.
CRIXIVAN must be taken at intervals of 8 hours. For optimal absorption, CRIXIVAN should be administered without food but with water 1 hour before or 2 hours after a meal. Alternatively, CRIXIVAN may be administered with other liquids such as skim milk, juice, coffee, or tea, or with a light meal, e.g., dry toast with jelly, juice, and coffee with skim milk and sugar; or corn flakes, skim milk and sugar. (See CLINICAL PHARMACOLOGY, Effect of Food on Oral Absorption.)
To ensure adequate hydration, it is recommended that adults drink at least 1.5 liters (approximately 48 ounces) of liquids during the course of 24 hours.
Dose reduction of CRIXIVAN to 600 mg every 8 hours should be considered when administering delavirdine 400 mg three times a day.
If indinavir and didanosine are administered concomitantly, they should be administered at least one hour apart on an empty stomach (consult the manufacturer's product circular for didanosine).
Dose reduction of CRIXIVAN to 600 mg every 8 hours is recommended when administering itraconazole 200 mg twice daily concurrently.
Dose reduction of CRIXIVAN to 600 mg every 8 hours is recommended when administering ketoconazole concurrently.
Dose reduction of rifabutin to half the standard dose (consult the manufacturer's product circular for rifabutin) and a dose increase of CRIXIVAN to 1000 mg every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.
The dosage of CRIXIVAN should be reduced to 600 mg every 8 hours in patients with mild-tomoderate hepatic insufficiency due to cirrhosis.
CRIXIVAN Capsules are supplied as follows:
No. 3756 — 200 mg capsules: semi-translucent white capsules coded “CRIXIVAN™ 200 mg” in blue.
NDC 0006-0571-43 unit-of-use bottles of 360 (with desiccant).
No. 3758 — 400 mg capsules: semi-translucent white capsules coded “CRIXIVAN™ 400 mg” in green. Available as:
NDC 0006-0573-62 unit-of-use bottles of 180 (with desiccant)
Bottles: Store in a tightly-closed container at room temperature, 15-30°C (59-86°F). Protect from moisture.
CRIXIVAN Capsules are sensitive to moisture. CRIXIVAN should be dispensed and stored in the original container. The desiccant should remain in the original bottle.
Dist. by: Merck Sharp & Dohme Corp., a subsidiary of MERCK & CO., INC., Whitehouse Station, NJ 08889, USA. Revised 03/2015This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 4/4/2016
Additional Crixivan Information
Crixivan - User Reviews
Crixivan User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.